Imperial College London
Dr Aarif O Eifan

Dr Aarif O Eifan

Faculty of Medicine, National Heart & Lung Institute

Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 3164a.eifan Website

 
 
//

Location

 

Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Steveling:2015:10.1186/s13601-015-0087-2,
author = {Steveling, EH and Lao-Araya, M and Koulias, C and Scadding, G and Eifan, A and James, LK and Dumitru, A and Penagos, M and Calderón, M and Andersen, PS and Shamji, M and Durham, SR},
doi = {10.1186/s13601-015-0087-2},
journal = {Clinical and Translational Allergy},
title = {Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes},
url = {http://dx.doi.org/10.1186/s13601-015-0087-2},
volume = {5},
year = {2015}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Seasonal Allergic Rhinitis is characterised by inflammation of the nasal mucosa upon exposure to common aeroallergens, affecting up to 20-25 % of the population. For those patients whose symptoms are not controlled by standard medical treatment, allergen specific immunotherapy is a therapeutic alternative. Although several studies have shown changes in immunologic responses as well as long term tolerance following treatment with a sublingual allergy immunotherapy tablet, a detailed time course of the early mechanistic changes of local and systemic T and B cell responses and the effects on B cell repertoire in the nasal mucosa have not been fully examined. METHODS/DESIGN: This is a randomized, double-blind, single-centre, placebo controlled, two arm time course study based in the United Kingdom comparing sublingual allergy immunotherapy tablet (GRAZAX(®), ALK-Abello Horsholm, Denmark) plus standard treatment with placebo plus standard treatment. Up to 50 moderate to severe grass pollen allergic participants will be enrolled to ensure randomisation of at least 44. Further, we shall enrol 20 non-atopic volunteers. Screening will be completed before eligible atopic participants are randomised to one of the two treatment arms in a 1 to 1 ratio. The primary endpoint will be the total nasal symptom score assessed over 60 min following grass pollen nasal allergen challenge after 12 months of treatment. Clinical assessments and/or mechanistic analyses on blood, nasal fluid, brushing and biopsies will be performed at baseline at 1, 2, 3, 4 (coinciding with the peak pollen season), 6 and 12 months of treatment. After 12 months of treatment, unblinding will take place. Those atopic participants receiving active treatment will continue therapy for another 12 months followed by a post treatment phase of 12 months. Assessments and collection of biologic samples from these participants will take place again at 24 and at 36 mon
AU  - Steveling,EH
AU  - Lao-Araya,M
AU  - Koulias,C
AU  - Scadding,G
AU  - Eifan,A
AU  - James,LK
AU  - Dumitru,A
AU  - Penagos,M
AU  - Calderón,M
AU  - Andersen,PS
AU  - Shamji,M
AU  - Durham,SR
DO  - 10.1186/s13601-015-0087-2
PY  - 2015///
SN  - 2045-7022
TI  - Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes
T2  - Clinical and Translational Allergy
UR  - http://dx.doi.org/10.1186/s13601-015-0087-2
UR  - http://hdl.handle.net/10044/1/40914
VL  - 5
ER  -
Download